• Boehringer Ingelheim Teams Up With Brainomix, New Diagnostic For Multiple Sclerosis, More

    Jul 25 | Diagnostics World | Researchers at The Australian National University (ANU) have developed a deep learning algorithm, known as DEPLOY, to classify central nervous system tumors into 10 major categories from histopathology images. The goal is to optimize treatment with a faster, more accessible diagnostic approach than the state-of-the-art practice of DNA methylation-based profiling, which can take weeks. More

  • Element Biosciences Commercializing Platform, NOWDiagnostics At-Home Tests, More

    Jul 24 | Diagnostics World | Element Biosciences nets $277 million to launch combined sequencing and cyto-profiling platform; NOWDiagnostics raises $22.5 million for at-home diagnostic tests; and more. More

  • Grassroots Initiative Helping Clinicians Better Treat Rare Disease Patients

    Jul 23 | Diagnostics World | A new web-based platform aims to standardize the care of rare disease patients in a wide range of settings and accelerate their diagnostic journey. The Rare Disease Clinical Activity Protocols (RareCAP) is effectively a collection of the latest research-based information and guidance about some of the more than 7,000 conditions affecting a small number of people. More

  • Cardiac Sarcoidosis: Exploring a Rare and Difficult-to-Diagnose Disease

    Jul 18 | Diagnostics World | Most of the time, sarcoidosis appears in the lungs and lymph nodes, but the heart is impacted in a smaller number of patients. Known as cardiac sarcoidosis (CS), this rare condition can lead to serious complications like arrhythmia or heart failure. Recently, Diagnostics World covered efforts to improve diagnostic and treatment options for sarcoidosis. More

  • Digital Endpoints Gaining Ground in Industry-Sponsored Trials

    Jul 16 | Diagnostics World | A recent analysis of interventional clinical trials by the Tufts Center for the Study of Drug Development (CSDD) has found that use of digital endpoints has been growing rapidly since 2015 with drug developers now initiating an average of about 35 such studies each year. News of the uptick isn’t entirely surprising, given mounting evidence that the approach can improve operational performance and ease patient burdens in clinical trials and in clinical practice, while [potentially] yielding financial net benefits to developers. More

  • Cool New Tech Tricks for Tackling Speed Bumps in Point-of-Care Histology

    Jul 11 | Diagnostics World | For more than 150 years now, medical scientists have been hunching over microscopes turning human tissue samples into crisp colored images that help pathologists diagnose diseases. Histology, as the field is known, has made an art of the complex business of creating high-quality microscope slides—and until recently done it in precisely the same way with consistently good results. More

  • AI Taking on the Holy Grail of Diagnostics: Predicting Drug Response

    Jul 10 | Diagnostics World | Machine learning models can be superior to radiologists when it comes to processing complex images and putting a predictive label on them, particularly at scale. The problems currently being studied in biomedicine with machine learning, such as identifying the subtype of cancer a patient has, are ones that have been largely ignored for a long time. More

  • Proscia, Nucleai Partner to Link Digital Pathology, AI-Predictive Biomarker Platforms

    Jul 09 | Diagnostics World | Proscia and Nucleai are partnering to integrate Nucleai’s predictive biomarker solutions into Proscia’s Concentriq software platform and make them available as part of Proscia’s AI-enabled pathology portfolio to better inform patient care. More

  • New AI System Detects Rare Forms of Epilepsy Better Than Traditional Models

    Jul 01 | Diagnostics World | Over 3.4 million people in the US and 65 million people worldwide are affected by epilepsy. To ensure that patients are getting the treatment they need, early detection is critical. Researchers at the University of Southern California have developed an AI system called NeuroGNN that can identify epilepsy by analyzing brain interactions with greater accuracy and efficiency. More

  • Follow the Money: Foresite Therapeutics’ New Fund Invests in Precision Therapeutics, Targeting Autoimmune, Inflammatory Diseases, More

    Jun 27 | Diagnostics World | Foresite Capital launches fund for three main areas: precision therapeutics, life science infrastructure, and healthcare delivery; Santa Ana Bio employs proteomic, transcriptomic, and genomic approaches to precisely characterize disease-specific subpopulations and identify targets only on disease-causing cell types leaving healthy cells unaffected; more. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more